tradingkey.logo

Telomir Pharmaceuticals Inc

TELO
1.150USD
+0.030+2.68%
終値 02/06, 16:00ET15分遅れの株価
38.91M時価総額
損失額直近12ヶ月PER

Telomir Pharmaceuticals Inc

1.150
+0.030+2.68%

詳細情報 Telomir Pharmaceuticals Inc 企業名

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease. It is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. It is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.

Telomir Pharmaceuticals Incの企業情報

企業コードTELO
会社名Telomir Pharmaceuticals Inc
上場日Feb 09, 2024
最高経営責任者「CEO」Aminov (Erez)
従業員数- -
証券種類Ordinary Share
決算期末Feb 09
本社所在地900 West Platt Street, Suite 200
都市TAMPA
証券取引所NASDAQ OMX - NASDAQ BASIC
United States of America
郵便番号33606
電話番号18138642562
ウェブサイトhttps://telomirpharma.com/
企業コードTELO
上場日Feb 09, 2024
最高経営責任者「CEO」Aminov (Erez)

Telomir Pharmaceuticals Incの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Erez Aminov
Mr. Erez Aminov
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.01M
+979885.00%
Dr. Matthew Paul Del Giudice, M.D.
Dr. Matthew Paul Del Giudice, M.D.
Independent Director
Independent Director
--
--
Mr. Matthew Pratt Whalen, CPA
Mr. Matthew Pratt Whalen, CPA
Director
Director
--
--
Mr. Alan Weichselbaum
Mr. Alan Weichselbaum
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Edward MacPherson
Mr. Edward MacPherson
Independent Director
Independent Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Erez Aminov
Mr. Erez Aminov
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.01M
+979885.00%
Dr. Matthew Paul Del Giudice, M.D.
Dr. Matthew Paul Del Giudice, M.D.
Independent Director
Independent Director
--
--
Mr. Matthew Pratt Whalen, CPA
Mr. Matthew Pratt Whalen, CPA
Director
Director
--
--
Mr. Alan Weichselbaum
Mr. Alan Weichselbaum
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Edward MacPherson
Mr. Edward MacPherson
Independent Director
Independent Director
--
--

収益内訳

会社から関連データがまだ開示されていません。
会社から関連データがまだ開示されていません。
事業別
地域別
会社から関連データがまだ開示されていません。

株主

更新時刻: Thu, Feb 5
更新時刻: Thu, Feb 5
株主統計
種類
株主統計
株主統計
比率
Bay Shore Trust
19.58%
Mira Pharmaceuticals, Inc
10.24%
McNulty (Brian Patrick)
5.46%
DeJoria (John Paul)
5.16%
The Vanguard Group, Inc.
3.31%
他の
56.24%
株主統計
株主統計
比率
Bay Shore Trust
19.58%
Mira Pharmaceuticals, Inc
10.24%
McNulty (Brian Patrick)
5.46%
DeJoria (John Paul)
5.16%
The Vanguard Group, Inc.
3.31%
他の
56.24%
種類
株主統計
比率
Corporation
29.82%
Individual Investor
15.16%
Investment Advisor
5.03%
Investment Advisor/Hedge Fund
1.05%
Hedge Fund
0.68%
Research Firm
0.13%
他の
48.12%

機関投資家保有株

更新時刻: Thu, Jan 1
更新時刻: Thu, Jan 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
105
2.37M
6.89%
-823.74K
2025Q3
97
2.75M
8.52%
-985.35K
2025Q2
89
13.66M
45.90%
+660.23K
2025Q1
87
13.90M
46.70%
+955.11K
2024Q4
74
13.75M
46.22%
+2.38M
2024Q3
65
14.68M
49.58%
+3.19M
2024Q2
47
12.97M
43.79%
+1.79M
2024Q1
17
12.67M
42.78%
+1.58M

株主動向

会社名
保有株式数
比率
変動額
変動率
日付
Bay Shore Trust
6.73M
19.58%
-89.00K
-1.30%
Dec 31, 2024
Mira Pharmaceuticals, Inc
3.52M
10.24%
+3.52M
--
Sep 29, 2025
McNulty (Brian Patrick)
1.88M
5.46%
-49.00K
-2.54%
Dec 31, 2024
DeJoria (John Paul)
1.77M
5.16%
+1.77M
--
Sep 09, 2025
The Vanguard Group, Inc.
1.10M
3.2%
-16.47K
-1.47%
Sep 30, 2025
Aminov (Erez)
1.01M
2.94%
+979.88K
+3288.20%
Dec 31, 2024
Eagle (Craig)
487.81K
1.42%
--
--
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
287.80K
0.84%
-69.21K
-19.39%
Sep 30, 2025
Millennium Management LLC
222.40K
0.65%
-25.30K
-10.21%
Sep 30, 2025
Geode Capital Management, L.L.C.
196.03K
0.57%
-850.00
-0.43%
Sep 30, 2025
詳細を見る

関連ETF

更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
iShares Micro-Cap ETF
0.01%
iShares Russell 2000 ETF
0%
Global X Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 Growth ETF
0%
iShares Micro-Cap ETF
比率0.01%
iShares Russell 2000 ETF
比率0%
Global X Russell 2000 ETF
比率0%
ProShares UltraPro Russell2000
比率0%
ProShares Hedge Replication ETF
比率0%
Proshares Ultra Russell 2000
比率0%
iShares Russell 2000 Value ETF
比率0%
iShares Russell 2000 Growth ETF
比率0%

配当金

過去5年間の配当金総支払額は 0.00 米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし

株式分割

日付
配当落ち日
種類
比率
データなし
日付
配当落ち日
種類
比率
データなし
KeyAI